Literature DB >> 15143103

Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Nicola Normanno, Massimo Di Maio, Francesco Perrone, Manuela Campiglio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15143103     DOI： 10.1200/JCO.2004.99.337

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.

Authors:  Hae Sun Jung; Gun-Woo Byun; Kyoung-Eun Lee; Yeung Chul Mun; Seung Hyun Nam; Jung Mi Kwon; Shi Nae Lee; Seock-Ah Im; Chu-Myong Seong; Soon Nam Lee
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

2.  Knockout of glucosidase II beta subunit inhibits growth and metastatic potential of lung cancer cells by inhibiting receptor tyrosine kinase activities.

Authors:  Worapong Khaodee; Suruk Udomsom; Phraepakaporn Kunnaja; Ratchada Cressey
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.